Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent in print and are also available online. Monographs can be customized to meet the needs of a facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.
Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800–322–4349. The January 2009 monograph topics are on lacosamide, fesoterodine, C1 inhibitor (human), silodosin, and cethromycin. The DUE is on lacosamide.
Get full access to this article
View all access options for this article.
References
1.
Lexiscan [package insert].Deerfield, IL: Astellas Pharma US, Inc; April 2008.
2.
Dipyridamole [package insert].Bedford, OH: Bedford Laboratories; February 2006.
3.
Adenoscan [package insert].Deerfield, IL: Astellas Pharma US, Inc; July 2005.
4.
HendelR.C., BatemanT.M., CerqueiraM.D.Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol.2005; 46(11): 2069–2075.
5.
HendelR.C., JamilT., GloverD.K.Pharmacologic stress testing: new methods and new agents. J Nucl Cardiol.2003; 10(2): 197–204.
6.
PatelR.N., ArteagaR.B., MandawatM.K., ThorntonJ.W., RobinsonV.J.Pharmacologic stress myocardial perfusion imaging. South Med J.2007; 100(10): 1006–1014.
7.
CerqueiraM.D.The future of pharmacologic stress: selective A2A adenosine receptor agonists. Am J Cardiol.2004; 94(2A): 33D–42D.
8.
GaoZ., LiZ., BakerS.P.Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists. J Pharmacol Exp Ther.2001; 298(1): 209–218.
9.
LieuH.D., ShryockJ.C., von MeringG.O.Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol.2007; 14(4): 514–520.
10.
ZablockiJ., PalleV., BlackburnB.2-substituted pi system derivatives of adenosine that are coronary vasodilators acting via the A2A adenosine receptor. Nucleosides Nucleotides Nucleic Acids.2001; 20(4-7): 343–360.
11.
ShryockJ., WuY.Receptor reserve is large for coronary hyperemia induced by regadenoson, a moderate affinity A2A-adenosine receptor agonist and vasodilator for cardiac perfusion imaging. J Nucl Cardiol.2007; 14(2): S63.
12.
CannonR.O., FreestoneS., MairS.J.A randomized, placebo-controlled, crossover, ascending dose tolerance and pharmacokinetic study of CVT-3146: a novel agent for potential use in myocardial perfusion imaging [abstract]. Clin Pharmacol Ther.2003; 73: P31.
13.
GordiT., BlackburnB., LieuH.Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol.2007; 47(7): 825–833.
14.
VaraniK., ShryockJ.C., BelardinelliL., BoreaP.A.Effects of CVT-3146, a novel coronary vasodilator under development for use in myocardial imaging, on A2A-adenosine receptors of human platelets and neutrophils [abstract]. J Nucl Cardiol.2005; 12(2): S76.
15.
ZhaoG., LinkeA., XuX.Comparative profile of vasodilation by CVT-3146, a novel A2A receptor agonist, and adenosine in conscious dogs. J Pharmacol Exp Ther.2003; 307(1): 182–189.
16.
ZhaoG., LinkeA., XuX.Comparison of vasodilation by CVT-3146, a novel A2A receptor agonist, and adenosine in different vascular beds in awake dogs [abstract]. J Am Coll Cardiol.2003; 41(suppl): 312A.
17.
DhallaA.K., XuJ., KussmaulW., KurnikP.P., PellegA., BelardinelliL.Differential vasodilatory effects of CVT-3146, an A2A adenosine receptor agonist in various vascular beds in anesthetized dogs [abstract]. J Am Coll Cardiol.2004; 43(suppl): 367A–368A.
18.
GordiT.T., OlmstedA., LieuH., BelardinelliL.A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an A2A adenosine receptor agonist, in healthy subjects [abstract]. J Nucl Cardiol.2005; 12(2): S74.
19.
GordiT.T., LieuH., OlmstedA., BelardinelliL.A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an A2A adenosine receptor agonist, suggests unit-based dosing in humans [abstract]. J Nucl Cardiol.2005; 12(2): S74.
20.
GordiT., FrohnaP., SunH.L., WolffA., BelardinelliL., LieuH.A population pharmacokinetic/pharmacodynamics analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet.2006; 45(12): 1201–1212.
ReyesE.E., StandbridgeK., NguyenP., OlmstedA., WongW., UnderwoodR.A comparison of the safety profile and tolerability of regadenoson and adenosine for myocardial perfusion scintography in older patients [abstract]. J Nucl Cardiol.2007; 14(2): S24.
24.
StandbridgeK., ReyesE.E., NguyenP., OlmstedA., WangW., UnderwoodR.The safety and efficacy of regadenoson myocardial perfusion scintography in women [abstract]. J Nucl Cardiol.2007; 14(2): S75.
25.
Regadenoson meets primary endpoint in first phase 3 trial [press release].Palo Alto, CA: CV Therapeutics, Inc; August 10, 2005.
26.
Regadenoson meets primary endpoint in second phase 3 clinical trial [press release].Palo Alto, CA: CV Therapeutics, Inc; December 4, 2006.
27.
IskandrianA.E., BatemanT.M., BelardinelliL.; ADAVNCE MPI Investigators. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol.2007; 14(5): 645–658.
28.
IskandrianA.E., BelardinelliL., BlackburnB., KristyR., WangW.Heart rate response to adenosine and regadenoson in patients with diabetes: evidence for sympathetic denervation [abstract]. J Nucl Cardiol.2007; 14(5): S127.
29.
ThomasG.S., ThompsonR.C., ShahM.Safety of regadenoson during submaximal exercise testing: a randomized, double-blind, placebo- and active-controlled trial (The RegEx Trial) [abstract]. J Nucl Cardiol.2007; 14(5): S109–S110.
30.
LeakerB.R., O'ConnorB., OlmstedA., MathurV.S., LieuH.D.Safety of regadenoson, an adenosine A2A receptor agonist, in patients with asthma: a randomized, double-blind, placebo-controlled trial [abstract]. J Nucl Cardiol.2007; 14(2): S58.
31.
Regadenoson. Drug Facts and Comparisons. factsandcomparisons4.0 [online]. 2008.Wolters Kluwer Health, Inc. Accessed April 28, 2008.
32.
ZhaoG., MessinaE., XuX.Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist. J Cardiovasc Pharmacol.2007; 49(6): 369–375.
33.
KoepfliP., SchepisT., GaemperliO.Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by PET [abstract]. Eur Heart J.2006; 27(Suppl 1): 175.
34.
GaemperliO., SchepisT., KoepfliP.Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography. A randomized, double-blind, placebo-controlled crossover trial. J Am Coll Cardiol.2008; 51(3): 328–329.
